Výsledky vyhledávání - "Sarah Schellhorn"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021

Autor: Rachel, Jaber Chehayeb, Annette, Hood, Xiaoliang, Wang, Rebecca, Miksad, Sarah, Schellhorn Mougalian, Maryam B, Lustberg, Shi-Yi, Wang, Rachel A, Greenup, Lajos, Pusztai, Natalia, Kunst

Publikováno v: JAMA Network Open. 5:e2244204

ImportanceAdvances in treatment of metastatic breast cancer (MBC) led to changes in clinical practice and treatment costs in the US over the past decade. There is limited information on current MBC treatment sequences and associated costs by MBC subt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff69d62ab789b8daed341c1b58fe0b40
https://doi.org/10.1001/jamanetworkopen.2022.44204

Zobrazit plný text záznamu

'The waiting is the worst': Development of a next day access (NDA) program for patients with cancer

Autor: Anne C. Chiang, Lisa Shomsky, Sarah Schellhorn Mougalian, Maureen Major Campos

Publikováno v: Journal of Clinical Oncology. 39:205-205

205 Background: Delays in access to treatment can cause anxiety and distress in patients with cancer. Time to treatment is increasing nationally, with retrospective analyses showing worse outcomes in patients with longer times to treatment initiation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::294edbfb1e26c1a1cea7713b1afc497a
https://doi.org/10.1200/jco.2020.39.28_suppl.205

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world clinical effectiveness of eribulin in metastatic breast cancer patients with visceral metastases in the United States

Autor: Marjorie E Zettler, Bruce A. Feinberg, Sarah Schellhorn Mougalian, Jonathan Kish, Jingchuan Zhang

Publikováno v: Journal of Clinical Oncology. 39:e13058-e13058

e13058 Background: Eribulin mesylate was approved in the United States (US) in 2010 for the treatment of metastatic breast cancer (mBC) after at least two prior chemotherapeutic regimens, which should have included an anthracycline and a taxane in ei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4281683795a315fc68d4523ad1e7876d
https://doi.org/10.1200/jco.2021.39.15_suppl.e13058

Zobrazit plný text záznamu

How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?

Autor: Mehra Golshan, Donald R. Lannin, Tara Sanft, Sarah Schellhorn Mougalian, Lajos Pusztai, Cary P. Gross, Elizabeth R Berger, Anees B. Chagpar, Michael DiGiovanna, Nina R. Horowitz

Publikováno v: Journal of Clinical Oncology. 39:e18708-e18708

e18708 Background: The COVID-19 pandemic has caused shifts in terms of cancer management, but the impact of this has not been well-elucidated in a contemporary cohort of patients in clinical practice in the US. We hypothesized that closure of operati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c3183cce6477786f2c8ea053c620125
https://doi.org/10.1200/jco.2021.39.15_suppl.e18708

Zobrazit plný text záznamu

Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer

Autor: Shi-Yi Wang, Lajos Pusztai, NR Horowitz, Brigid K. Killelea, Anees B. Chagpar, Lannin, Sarah Schellhorn Mougalian

Publikováno v: Cancer Research. 76:P1-09

Introduction Although racial disparities in breast cancer treatment have been well documented, data regarding differences in response to neoadjuvant chemotherapy are few. In 2010 the National Cancer Database (NCDB) included a new variable, documentin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75e5d433206cb02910aa4156ce01107a
https://doi.org/10.1158/1538-7445.sabcs15-p1-09-01

Zobrazit plný text záznamu

Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study

Autor: E Hofstatter, Gang Han, Andrea Silber, Gina G. Chung, AP Jhaveri, Maysa M. Abu-Khalaf, L Pusztai, Kerin B. Adelson, Tara Sanft, Michael DiGiovanna, Sarah Schellhorn Mougalian, Cary P. Gross, Lianne Epstein

Publikováno v: Cancer Research. 76:P5-11

Introduction: Approximately 75% of stage I-III breast cancers are hormone receptor (HR) positive for which the standard of care is 5-10 years of adjuvant endocrine therapy, which has been shown to reduce recurrences and improve survival. Unfortunatel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d3172aa87eebb22984340bda8773695
https://doi.org/10.1158/1538-7445.sabcs15-p5-11-03

Zobrazit plný text záznamu

Abstract PD6-07: Trends in the cost of care for breast cancer among women with commercial insurance

Autor: Ahmedin Jemal, Rachel A. Freedman, Cary P. Gross, HJ Henk, Lindsey R. Sangaralingham, Kathryn J. Ruddy, Theresa H.M. Keegan, Nilay Shah, Charles L. Loprinzi, Sarah Schellhorn Mougalian

Publikováno v: Cancer Research. 79:PD6-07

Background: Breast cancer care imposes a significant financial burden to U.S. healthcare systems and has become a key focus in the health care debate. Therapies for breast cancer are expensive, and the economic burden of these therapies may be rising

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6da388841406b1b9861ac6128868f11a
https://doi.org/10.1158/1538-7445.sabcs18-pd6-07

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání